Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Progesterone Receptor Agonists Market: Competitive Landscape, Pipeline, and Market Analysis 2023
Progesterone Receptor Agonists Market: Competitive Landscape, Pipeline, and Market Analysis 2023
Progestins are the substances that convert the estrogen-primed proliferative endometrium to secretory and maintain pregnancy in animals spayed after conception. Progesterone is a 21-carbon steroid derived from cholesterol that is secreted by the corpus luteum in the later half of the menstrual cycle under the influence of luteinizing Hormone (LH). Progesterone Receptor Agonists are the Progesterone derivatives that act as substitutes for Progesterone and function to prepare the uterus for nidation and maintenance of pregnancy. It does this by preventing endometrial shedding, decreasing uterine motility, and inhibiting immunological rejection of the fetus. These agonists are used in Hormone Replacement Therapy (HRT), Threatened Abortion, Endometriosis, Dysfunctional Uterine Bleeding, and others. The development of new and novel molecules by the market players is imminent. Extensive research is being conducted globally to discover new and novel molecules to be used as Progesterone Receptor Agonists like etonogestrel are used to prevent pregnancy. The development and launch of new products will thus increase the market’s revenue in the forecasted years. According to the NHSBSA statistics of England, in 2021/2022, an estimated 1.93 million identified patients were prescribed HRT, which was an increase of 30.5% than the last year. Also, according to the U.S. Department of Health and Human Services report in 2021, 11% - 13% of women of reproductive age at any given time experience abnormal uterine bleeding. This increases with age, with prevalence increasing to nearly 24% in women in the age range of 36 to 40 years. There is a great demand for medical intended to provide relief from these disorders and drive the growth of the market.
A number of these inhibitors are in the market, while many are in ongoing clinical trials. Many companies have various products in their pipelines, with 48 products in different stages of clinical trials. 9 products in Phase 4, 14 in Phase 3, 5 in Phase 2, and 2 in Phase 1 of the clinical trials.
Key Developments of Progesterone Receptor Agonists
for management of moderate to severe pain associated with endometriosis.
was approved in Europe by the EU as Ryeqo for the treatment of moderate to severe symptoms of Uterine Fibroids in women of reproductive age.
for heavy menstrual bleeding associated with Uterine Fibroids.
Approved molecules of Progesterone Receptor Agonists
Drugs In The Pipeline Of Progesterone Receptor Agonists
Clinical Activity and Developments of Progesterone Receptor Agonists
As of July 2023, 31 companies have approximately 46 products for 270 diseases. For these diseases, 293 trials are being conducted by players globally. For instance,
|
Molecule name |
Number of studies |
|
Nexplanon (etonogestrel implant) |
77 |
|
Utrogestan (progesterone) |
54 |
|
Visanne (dienogest) |
37 |
|
Climara (estradiol) |
36 |
|
Zoely (nomegestrol/estradiol) |
22 |
Drugs like Nexplanon (etonogestrel implant) and Utrogestan (progesterone) have been approved by the FDA and other regulatory agencies to treat various diseases. Nexplanon is a small patch under the skin that helps prevent pregnancy by releasing progesterone into the bloodstream. Utrogestan is also used to treat problems related to hormonal imbalance and disorders related to infertility, irregular menses, and abnormal uterine bleeding. These drugs are used in Hormone Replacement Therapy (HRT) in non-hysterectomized women, dysfunctional uterine bleeding, Endometriosis, Premenstrual syndrome, Endometrial carcinoma, Threatened abortion, and others. Combination pills are also available to nullify the adverse effect of another ingredient in the formulation with better efficacy and safety profile.
Nexplanon had net sales of $834 million globally in the financial year 2022, while the net sales were $769 million in the financial year 2021. The net sales in the USA were $573 million in the financial year 2022, up from $532 million in the financial year 2021. Endometriosis is a disease in which tissue similar to the lining of the uterus grows outside the uterus, causing severe pain in the pelvic region. According to the WHO 2023 report, around 10% (190 million) of reproductive-age females are affected by Endometriosis. According to Office on Women’s Health 2023 report, around 6.5 million US women have endometriosis. It is more common within the age of 30 to 50 years, which makes it harder to get pregnant. There is a good opportunity for the market players to launch new products seeing the rising prevalence of the diseases.
Latin America
Europe
Asia Pacific
Middle East
North America
Download Free Sample Report
Nexplanon (etonogestrel implant), Utrogestan (progesterone), Visanne (dienogest), Climara (estradiol), and Zoely (nomegestrol/estradiol) are approved by various regulatory agencies.
These are used in Hormone Replacement Therapy (HRT), in Threatened Abortion, Endometriosis, Dysfunctional Uterine Bleeding, and others.
Organon Group, Besins Healthcare, Mochida Pharmaceutical, Bausch Health, and Novartis are some of the major market players for GABA A Receptor Agonists.
Rising incidence of diseases, improvement in technologies, development of new treatment lines in the market and rising incidence of threatened abortions, Hormonal disbalance causing dysfunctional uterine bleeding, Endometriosis, and others are the critical opportunities for Progesterone Receptor Agonists in the market.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.